me-troe-NI-da-zole
REMS
Clostridioides difficile
-associated diarrhea (CDAD).Spectrum:
Absorption: 80% absorbed after oral administration. Minimal absorption after topical or vaginal application.
Distribution: Widely distributed into most tissues and fluids, including CSF.
Half-Life: Neonates: 25–75 hr; Children and adults: 6–12 hr.
(PO, IV = plasma concentrations; topical = improvement in rosacea)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | rapid | 1–3 hr | 8 hr |
| PO-ER | rapid | unknown | up to 24 hr |
| IV | rapid | end of infusion | 6–8 hr |
| Topical | 3 wk | 9 wk | 12 hr |
| Vaginal | unknown | 6–12 hr | 12 hr |
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP), DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN), urticaria,
topical only
burning, mild dryness, skin irritation, transient rednessEENT: hearing impairment, optic neuropathy, tearing (topical only)
GI: abdominal pain, anorexia, nausea, diarrhea, dry mouth, furry tongue, glossitis, unpleasant taste, vomiting
Hemat: leukopenia
Local: phlebitis at IV site
Neuro: dizziness, headache, aseptic meningitis (IV), encephalopathy (IV), peripheral neuropathy, psychosis, SEIZURES
Misc: superinfection
Drug-drug:
H. pylori
: 250 mg 4 times daily or 500 mg twice daily for 1–2 wk (with other agents). Antibiotic associatedClostridioides difficile
-associated diarrhea (CDAD): 250–500 mg 3–4 times/day for 10–14 days.Clostridioides difficile
-associated diarrhea (CDAD): 30 mg/kg/day divided every 6 hr for 7–10 days.H. pylori
: 15–20 mg/kg/day divided twice daily for 4 wk.Lab Test Considerations:
IV Administration:
NDC Code